In accord with the observed growth-supporting function of NFYC-AS1, survival analyses revealed that its higher expression in tumors is associated with significantly increased risk of disease progression in LUSC patients (Fig. 4J) and a trend for decreased overall survival in SCLC patients (Supplementary Fig. S4E). Here, NFYC is linked to small cell lung carcinoma.